Stemline Therapeutics (STML) – Investment Analysts’ Recent Ratings Changes

Stemline Therapeutics (NASDAQ: STML) recently received a number of ratings updates from brokerages and research firms:

  • 1/21/2020 – Stemline Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
  • 1/21/2020 – Stemline Therapeutics was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 1/21/2020 – Stemline Therapeutics had its price target lowered by analysts at HC Wainwright from $35.00 to $20.00. They now have a “buy” rating on the stock.
  • 1/16/2020 – Stemline Therapeutics had its price target lowered by analysts at Wedbush from $17.00 to $14.00. They now have an “outperform” rating on the stock.
  • 1/14/2020 – Stemline Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
  • 1/10/2020 – Stemline Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 12/27/2019 – Stemline Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/24/2019 – Stemline Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $18.00 price target on the stock.
  • 12/11/2019 – Stemline Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
  • 11/25/2019 – Stemline Therapeutics is now covered by analysts at Alliance Global Partners. They set a “buy” rating and a $21.00 price target on the stock.

Stemline Therapeutics stock opened at $6.92 on Wednesday. The firm has a market cap of $352.41 million, a price-to-earnings ratio of -2.87 and a beta of 1.40. Stemline Therapeutics Inc has a 52 week low of $6.01 and a 52 week high of $18.22. The business’s 50-day moving average price is $9.77 and its 200 day moving average price is $11.21.

Stemline Therapeutics (NASDAQ:STML) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.08. The company had revenue of $13.33 million for the quarter, compared to analyst estimates of $13.40 million. On average, sell-side analysts anticipate that Stemline Therapeutics Inc will post -1.81 earnings per share for the current fiscal year.

In related news, COO Kenneth Hoberman sold 13,228 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $10.37, for a total transaction of $137,174.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.10% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Stemline Therapeutics by 51.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,297 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 1,466 shares during the period. Bank of Montreal Can acquired a new stake in Stemline Therapeutics during the second quarter worth about $52,000. Tower Research Capital LLC TRC grew its holdings in Stemline Therapeutics by 364.4% during the third quarter. Tower Research Capital LLC TRC now owns 7,115 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 5,583 shares during the period. JPMorgan Chase & Co. grew its holdings in Stemline Therapeutics by 18.5% during the second quarter. JPMorgan Chase & Co. now owns 11,004 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 1,715 shares during the period. Finally, Metropolitan Life Insurance Co NY grew its holdings in Stemline Therapeutics by 56.7% during the first quarter. Metropolitan Life Insurance Co NY now owns 13,358 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 4,835 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Read More: Real Estate Investment Trust (REIT) ETF

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.